CNETS Board Member Awareness

CNETS Board Member Awareness Patient Education and Fundraising A core function of CNETS is to offer the Canadian neuroendocrine cancer community useful, [...]

By |2021-11-05T04:34:17-04:00November 4th, 2021|Awareness|Comments Off on CNETS Board Member Awareness

Pewter Zebra Keyfobs/Pendants

Volunteers create one-of-a-kind handmade Pewter Zebra Keyfobs/Pendants to help raise awareness & funds for CNETS Al Gillis is a neuroendocrine cancer patient and member of the Toronto Patient and [...]

By |2021-09-11T09:23:41-04:00August 23rd, 2021|Awareness, News|Comments Off on Pewter Zebra Keyfobs/Pendants

Temozolomide Access in Ontario

CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]

By |2021-07-07T21:48:16-04:00July 6th, 2021|Treatment News|Comments Off on Temozolomide Access in Ontario

Lutathera Funded in Saskatchewan

As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]

By |2021-07-06T18:30:28-04:00July 6th, 2021|Treatment News|Comments Off on Lutathera Funded in Saskatchewan

LUTATHERA Funded In British Columbia

CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide [...]

By |2021-05-30T15:16:40-04:00March 8th, 2021|Treatment News|Comments Off on LUTATHERA Funded In British Columbia
Go to Top